Isavuconazole safe and effective to treat aspergillus infection in patients with cancer
the ONA take:
According to new research presented at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014), isavuconazole is as effective as voriconazole for the treatment of aspergillus infection in patients with cancer. In the phase 3 study comparing isavuconazole, new antifungal agent, with voriconazole in patients with uncontrolled cancer, researchers found that the two agents were equally efficacious against the invasive fungal disease.
Furthermore, researchers observed fewer adverse effects associated with isavuconazole versus voriconazole. Compared with those that took voriconzaole, patients who took isavuconazole had less ocular, epidermal, and hepatobiliary toxicity.
Fungal infections caused by aspergillus and other fungi can be particularly harmful in immunocompromised patients undergoing treatment for cancer. These fungal infections often increase morbidity and mortality in these patients, especially those with hematological malignancies like leukemia and lymphoma.
Based on the results of the study, Astellas and Basilea Pharmaceutica International Ltd. have submitted a new drug application to the U.S. Food and Drug Administration (FDA) for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis.
Isavuconazole as effective as voriconazole for treatment of aspergillus infection in patients with cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|